FDA approves a liquid form of Kamada's AATD drug Glassia

07/5/2010 | Reuters

The FDA approved a liquid version of Glassia, Kamada's intravenous drug for alpha-1 antitrypsin deficiency, a condition that can lead to lung-tissue damage and emphysema. Kamada said it is looking for a partner to develop the treatment for other indications.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA